Close

Form 10-Q Golden Developing Soluti For: Jun 30

August 15, 2022 2:10 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
0001736865 false --12-31 2022 Q2 No Yes 0001736865 2022-01-01 2022-06-30 0001736865 2022-08-15 0001736865 2022-06-30 0001736865 2021-12-31 0001736865 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001736865 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001736865 2022-04-01 2022-06-30 0001736865 2021-04-01 2021-06-30 0001736865 2021-01-01 2021-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2020-12-31 0001736865 us-gaap:CommonStockMember 2020-12-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001736865 us-gaap:RetainedEarningsMember 2020-12-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2020-12-31 0001736865 us-gaap:NoncontrollingInterestMember 2020-12-31 0001736865 2020-12-31 0001736865 DVLP:PreferredStockSeriesAMember 2021-03-31 0001736865 us-gaap:CommonStockMember 2021-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001736865 us-gaap:RetainedEarningsMember 2021-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2021-03-31 0001736865 2021-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2021-12-31 0001736865 us-gaap:CommonStockMember 2021-12-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001736865 us-gaap:RetainedEarningsMember 2021-12-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-12-31 0001736865 us-gaap:NoncontrollingInterestMember 2021-12-31 0001736865 DVLP:PreferredStockSeriesAMember 2022-03-31 0001736865 us-gaap:CommonStockMember 2022-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001736865 us-gaap:RetainedEarningsMember 2022-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2022-03-31 0001736865 2022-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001736865 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001736865 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-01-01 2021-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001736865 2021-01-01 2021-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2021-04-01 2021-06-30 0001736865 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001736865 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-04-01 2021-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001736865 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001736865 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-01-01 2022-03-31 0001736865 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001736865 2022-01-01 2022-03-31 0001736865 DVLP:PreferredStockSeriesAMember 2022-04-01 2022-06-30 0001736865 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001736865 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-04-01 2022-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2021-06-30 0001736865 us-gaap:CommonStockMember 2021-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001736865 us-gaap:RetainedEarningsMember 2021-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2021-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2021-06-30 0001736865 2021-06-30 0001736865 DVLP:PreferredStockSeriesAMember 2022-06-30 0001736865 us-gaap:CommonStockMember 2022-06-30 0001736865 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001736865 us-gaap:RetainedEarningsMember 2022-06-30 0001736865 DVLP:GoldenDevelopingSolutionsShareOfEquityDeficitMember 2022-06-30 0001736865 us-gaap:NoncontrollingInterestMember 2022-06-30 0001736865 DVLP:PuraVidaVitaminsMember 2018-07-01 0001736865 DVLP:PuraVidaVitaminsMember 2021-12-31 0001736865 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001736865 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001736865 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001736865 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001736865 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001736865 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001736865 DVLP:VendorMember DVLP:NotePayableAgreementMember 2020-12-31 0001736865 DVLP:NotePayableToRelatedPartyMember 2018-05-01 2018-05-31 0001736865 DVLP:CEOMember 2021-02-01 2021-02-28 0001736865 2022-05-01 2022-05-31 0001736865 DVLP:NotePayableToRelatedPartyMember 2022-06-30 0001736865 DVLP:NotePayableToRelatedPartyMember 2021-12-31 0001736865 us-gaap:UnsecuredDebtMember 2020-01-14 0001736865 us-gaap:UnsecuredDebtMember 2020-01-13 2020-01-14 0001736865 us-gaap:UnsecuredDebtMember 2020-01-01 2020-01-14 0001736865 us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001736865 2022-01-01 2022-01-27 0001736865 DVLP:LenderMember 2022-01-01 2022-01-27 0001736865 DVLP:LenderMember 2022-01-27 0001736865 us-gaap:UnsecuredDebtMember 2022-01-27 0001736865 us-gaap:UnsecuredDebtMember 2022-01-01 2022-01-27 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-03-31 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2022-06-01 2022-06-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-06-01 2022-06-30 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2022-06-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-06-30 0001736865 2021-11-03 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-11-03 0001736865 us-gaap:DebtMember 2022-06-30 0001736865 us-gaap:DebtMember 2022-01-01 2022-06-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-11-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2021-11-01 2021-11-30 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2021-11-01 2021-11-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2021-11-01 2021-11-30 0001736865 DVLP:LenderMember us-gaap:CommonStockMember 2021-11-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2021-11-30 0001736865 DVLP:Debt1Member 2022-06-30 0001736865 DVLP:Debt1Member 2022-01-01 2022-06-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-03-29 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-03-02 2022-03-29 0001736865 DVLP:Debt2Member 2022-06-30 0001736865 DVLP:Debt2Member 2022-01-01 2022-06-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-04-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-04-01 2022-04-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-04-01 2022-04-30 0001736865 us-gaap:WarrantMember DVLP:LenderMember 2022-04-30 0001736865 DVLP:Debt3Member 2022-06-30 0001736865 DVLP:Debt3Member 2022-01-01 2022-06-30 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-05-09 0001736865 DVLP:SeniorSecuredConvertiblePromissoryNoteMember 2022-05-01 2022-05-09 0001736865 DVLP:Debt4Member 2022-06-30 0001736865 DVLP:Debt4Member 2022-01-01 2022-06-30 0001736865 us-gaap:MeasurementInputExpectedDividendRateMember 2022-01-01 2022-06-30 0001736865 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-01 2022-06-30 0001736865 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-01 2022-06-30 0001736865 us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-06-30 0001736865 us-gaap:MeasurementInputSharePriceMember 2022-01-01 2022-06-30 0001736865 2019-06-30 0001736865 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001736865 us-gaap:WarrantMember 2022-06-30 0001736865 us-gaap:WarrantMember 2021-12-31 0001736865 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001736865 DVLP:OfficeSpaceLeaseMember 2022-06-30 0001736865 DVLP:WarehouseSpaceLeaseMember 2022-06-30 0001736865 DVLP:OfficeAndWarehouseSpaceColoradoMember 2019-12-31 0001736865 DVLP:OfficeAndWarehouseSpaceColoradoMember 2022-01-01 2022-06-30 0001736865 2020-01-01 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure DVLP:Integer

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended June 30, 2022

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Transition Period of ____________________ to ______________________

 

Commission file number: 000-54208

 

GOLDEN DEVELOPING SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   82-2911016

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

PO Box 460573

Fort Lauderdale, FL 33346

(Address of principal executive offices) (Zip Code)

 

623-826-5206

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit such files). YES NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at August 15, 2022
Common Stock, $.0001 par value   810,126,424

 

 

   

 

 

INDEX

 

    Page No.
     
PART I - FINANCIAL INFORMATION  
     
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS: 3
     
  Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 (unaudited) 3
     
  Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited) 4
     
  Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the Six Months Ended June 30, 2022 and 2021 (unaudited) 5
     
  Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (unaudited) 6
     
  Notes to Consolidated Financial Statements (unaudited) 7
     
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 16
     
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 19
     
ITEM 4. CONTROLS AND PROCEDURES 19
     
PART II - OTHER INFORMATION 21
     
ITEM 1. LEGAL PROCEEDINGS 21
     
ITEM 1A. RISK FACTORS 21
     
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 21
     
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 21
     
ITEM 4. MINE SAFETY DISCLOSURE 21
     
ITEM 5. OTHER INFORMATION 21
     
ITEM 6. EXHIBITS 22

 

 2 

 

 


PART I — FINANCIAL INFORMATION

 

Item 1. Consolidated Financial Statements.

 

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

           
   June 30   December 31, 
   2022   2021 
ASSETS        
Current assets:          
Cash and cash equivalents  $68,057   $10,735 
           
Total current assets   68,057    10,735 
           
           
Total assets  $68,057   $10,735 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable and accrued expenses  $219,317   $201,390 
Right of use liabilities - operating leases short-term   242,001    242,001 
Derivative liability   19,303    219,625 
Notes payable - related party   6,117    31,317 
Acquisition notes payable   50,000    50,000 
Note payable   90,214    90,214 
Convertible notes payable, net of debt discounts   182,866    163,609 
           
Total current liabilities   809,818    998,156 
           
Total liabilities   809,818    998,156 
           
Commitments and Contingencies        
           
Stockholders' equity:          
Preferred stock, 35,000,000 shares authorized, $0.0001 par value, Series A Preferred stock, 1 share authorized, 1 issued and outstanding        
Common stock, 4,000,000,000 shares authorized, $0.0001 par value, 785,327,851 and 698,127,851 issued and outstanding, respectively   78,532    69,812 
Additional paid-in capital   11,739,323    11,295,446 
Accumulated deficit   (12,559,616)   (12,352,679)
Total stockholders' equity   (741,761)   (987,421)
           
Total liabilities and stockholders' equity  $68,057   $10,735 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 3 

 

 

 

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

                     
   Three Months Ended   Six Months Ended 
   June 30, 2022   June 30, 2021   June 30, 2022   June 30, 2021 
                 
Revenue  $   $   $   $ 
Cost of revenue                
                     
Gross profit                
                     
Operating Expenses:                    
Professional fees   112,489    12,159    124,510    20,459 
General and administrative   50,656    324    96,865    5,713 
                     
Total operating expenses   163,145    12,483    221,375    26,172 
                     
Loss from Operations   (163,145)   (12,483)   (221,375)   (26,172)
                     
Other Income (Expense)                    
Gain on settlement of liabilities           11,000    58,617 
Derivative gain (loss)   23,574    31,011    148,465    (82,259)
Interest expense, net   (83,418)   (41,415)   (145,027)   (63,910)
                     
Net Income (loss) , before tax   (222,989)   (22,887)   (206,937)   (113,724)
                     
Income tax expense                
                     
Net Income (Loss)  $(222,989)  $(22,887)  $(206,937)  $(113,724)
                     
Net income (loss) from per share - basic  $(0.00)  $(0.00)  $(0.00)  $(0.00)
Net income (loss) from per share - dilutive  $(0.00)  $(0.00)  $   $(0.00)
                     
Weighted average shares outstanding - basic   764,605,629    545,841,084    738,475,365    545,841,084 
Weighted average shares outstanding - dilutive   764,605,629    545,841,084    738,475,365    545,841,084 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 

 4 

 

 

 

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

(UNAUDITED)

 

                                              
   Series A Preferred Stock   Common Stock   Additional Paid-in   Accumulated   Golden Developing Solutions Share of Equity  

Non

Controlling

   Total Stockholders' Equity 
   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit)   Interest   (Deficit) 
                                     
Balance December 31, 2020   1        541,507,751    54,150    10,579,303    (11,722,355)   (1,088,902)   (54,256)   (1,143,158)
                                              
Common shares and warrants issued for deferred offering costs           30,000,000    3,000    37,707        40,707        40,707 
                                              
Beneficial conversion feature upon issuance on convertible debt                   9,293        9,293        9,293 
                                              
Net loss                       (90,837)   (90,837)       (90,837)
                                              
Balance March 31, 2021   1        571,507,751    57,150    10,626,303    (11,813,192)   (1,129,739)   (54,256)   (1,183,995)
                                              
Net loss                       (22,887)   (22,887)       (22,887)
                                              
Balance June 30, 2021   1   $    571,507,751    57,150    10,626,303    (11,836,079)  $(1,152,626)  $(54,256)  $(1,206,882)
                                              
Balance December 31, 2021   1        698,127,851    69,812    11,295,446    (12,352,679)   (987,421)       (987,421)
                                              
Common shares issued due to conversion of note           12,000,000    1,200    17,800        19,000        19,000 
                                              
Common shares issued for cash proceeds           12,500,000    1,250    48,750        50,000        50,000 
                                              
Common shares issued for payment of services           10,200,000    1,020    18,220        19,240        19,240 
                                              
Beneficial conversion feature                   7,500        7,500        7,500 
                                              
Settlement of derivative liability through note conversion                   51,857        51,857        51,857 
                                              
Net income                       16,052    16,052         16,052 
                                              
Balance March 31, 2022   1        732,827,851    73,282    11,439,573    (12,336,627)   (823,772)       (823,772)
                                              
Common shares issued for cash proceeds           47,500,000    4,750    185,250        190,000        190,000 
                                              
Common shares issued for payment of services           5,000,000    500    17,500        18,000        18,000 
                                              
Beneficial conversion feature                   86,888        86,888        86,888 
                                              
Warrants issued for deferred offering costs                   10,112        10,112        10,112 
                                              
Net income                       (222,989)   (222,989)        (222,989)
                                              
Balance June 30, 2022   1   $    785,327,851   $78,532   $11,739,323   $(12,559,616)  $(741,761)  $   $(741,761)

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 

 5 

 

 

GOLDEN DEVELOPING SOLUTIONS, INC

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

           
   Six Months Ended 
   June 30, 2022   June 30, 2021 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)  $(206,937)  $(113,724)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:          
Stock-based compensation   37,240     
Note payable issued for services   75,000     
Derivative (gain) loss   (148,465)   53,448 
Amortization of debt discount and deferred financing costs   119,257    32,453 
Interest expense from derivative liability in excess of principal       28,811 
Gain on settlement of debt   (11,000)   (58,617)
Net Changes in:          
Accounts payable and accrued expenses   17,927    9,040 
Net cash used in operating activities   (116,978)   (48,589)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payments on notes payable   (70,000)    
Payments on related party loans   (25,200)    
Proceeds from convertible notes payable   29,500    50,000 
Net proceeds from the sale of common shares   240,000     
Net cash provided by financing activities   174,300    50,000 
           
NET CHANGE IN CASH AND CASH EQUIVALENTS   57,322    1,411 
           
CASH AND CASH EQUIVALENTS, beginning of period   10,735     
           
CASH AND CASH EQUIVALENTS, end of period  $68,057   $1,411 
           
Supplemental disclosures:          
Cash paid for income taxes  $   $ 
Cash paid for interest  $   $ 
           
Noncash activities          
Beneficial conversion feature upon issuance of convertible notes  $94,388   $9,293 
Common stock and warrants issued for deferred financing costs  $10,112   $40,707 
Settlement of debt paid directly by related party  $   $25,200 
Conversion and settlement of note  $19,000   $ 
Settlement of derivative liability on conversion  $51,857   $ 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 6 

 

 

GOLDEN DEVELOPING SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1 DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

 

Description of Business. Golden Developing Solutions, Inc. (the “Company” or “GDS”) was organized as a corporation in Nevada in 1998 as American Associates Group. In 2007 the name was changed to Clean Hydrogen Producers, Ltd before being changed in April of 2017 to Golden Developing Solutions, Inc. The Company has structured itself in 2017 as a cannabis holding company and intends to make additional acquisitions in the industry in the near future.

 

Basis of Presentation. The accompanying unaudited financial statements of Golden Developing Solutions, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, the financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the condensed financial statements not misleading. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the final results that may be expected for the year ended December 31, 2022. For more complete financial information, these unaudited financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2021. Notes to the consolidated financial statements which would substantially duplicate the disclosures contained in the annual financial statements for the most recent fiscal period have been omitted.

 

Use of Estimates in Financial Statement Preparation. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Principles of Consolidation. The Company prepares its consolidated financial statements on the accrual basis of accounting. The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, all of which have a fiscal year end of December 31. All intercompany accounts, balances and transactions have been eliminated in the consolidation. The Company also consolidates any variable interest entities for which the Company is the primary beneficiary based on whether the Company has the ability to direct the activities that most significantly impact the entities economic performance.

 

On April 27, 2018, the Company incorporated Pura Vida Vitamins, LLC as a wholly owned subsidiary. Pura Vida Vitamins, LLC entered into two consulting agreements with individuals that paid each consultant $6,000 per month in cash, additional bonuses depending on certain sales-related milestones, and 20,500,000 shares each for the completion of certain sales-related milestones, of which none were earned by either consultant. On July 1, 2018, the Company reorganized the entity to be a joint venture in which it owns 50%, in exchange for the cancelation of these consulting agreements. During the year ended December 31, 2021 the Company wrote off the balances for the non-controlling interest investment due to the dissolution of the joint venture, resulting in a loss of $53,442.

 

On September 26, 2018, the Company incorporated Tasos Media LLC as a wholly owned subsidiary.

 

On December 1, 2021, the Company incorporated Renown Pharmaceuticals LLC as a wholly owned subsidiary in the state Florida. In July 2022, the domicile was move to Delaware.

 

Goodwill, Intangible Assets, and Long-Lived Assets. Goodwill is carried at cost and is not amortized. The Company tests goodwill for impairment on an annual basis, relying on a number of factors including operating results, business plans, economic projections, anticipated future cash flows and marketplace data. Company management uses its judgment in assessing whether goodwill has become impaired between annual impairment tests according to specifications set forth in ASC 350.

 

 

 7 

 

 

The fair value of the Company’s reporting unit is dependent upon the Company’s estimate of future cash flows and other factors. The Company’s estimates of future cash flows include assumptions concerning future operating performance and economic conditions and may differ from actual future cash flows. Estimated future cash flows are adjusted by an appropriate discount rate derived from the Company’s market capitalization plus a suitable control premium at date of the evaluation.

 

The financial and credit market volatility directly impacts the Company’s fair value measurement through the Company’s weighted average cost of capital that the Company uses to determine its discount rate and through the Company’s stock price that the Company uses to determine its market capitalization. Therefore, changes in the stock price may also affect the amount of impairment recorded.

 

The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.

 

The Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset.

 

Fair Value of Financial Instruments

 

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the use of inputs used in valuation methodologies into the following three levels:

 

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.

 

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

 

Level 3: Significant unobservable inputs which reflect a reporting entity’s own assumptions about the assumptions that market participants would use for pricing an asset or liability. For example, level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

 

The following table summarizes fair value measurements by level at June 30, 2022 and December 31, 2021, measured at fair value on a recurring basis:

                
June 30, 2022  Level 1   Level 2   Level 3   Total 
Assets                    
None  $   $   $   $ 
                     
Liabilities                    
Derivative liabilities  $   $   $19,303   $19,303 

 

 

December 31, 2021  Level 1   Level 2   Level 3   Total 
Assets                    
None  $   $   $   $ 
                     
Liabilities                    
Derivative liabilities  $   $   $219,625   $219,625 

 

 

 8 

 

 

The recorded amounts of financial instruments, including cash equivalents, investments, accounts payable, accrued expenses, note payable and loan from related parties approximate their market values as of June 30, 2022 and December 31, 2021 due to the intended short-term maturities of these financial instruments.

 

Derivative Financial Instruments

 

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. The Company’s policy is to evaluate for reclassification contracts with the earliest maturity date first.

 

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Selling, General and Administrative Expenses. Selling, general and administrative expenses include advertising and promotional costs and research and development costs. Also included in Selling, general and administrative expenses are share-based compensation, certain warehousing fees, non-manufacturing overhead, personnel and related expenses, rent on operating leases, and professional fees.

 

Stock-Based CompensationThe Company applies Topic 718 “Share-Based Payments” (“Topic 718”) to share-based compensation, which requires the measurement of the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award. Compensation cost is recognized when the event occurs. The Black-Scholes option-pricing model is used to estimate the fair value of options granted.

 

The Company accounts for equity-based transactions with non-employees under the provisions of ASC Topic No. 505-50, “Equity-Based Payments to Non-Employees” (“Topic No. 505-50”). Topic No. 505-50 establishes that equity-based payment transactions with non-employees shall be measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

 

Basic Earning (Loss) Per Share. The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share.” ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. 

 

Recently Issued Accounting Standards.

 

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

 

NOTE 2 - GOING CONCERN AND LIQUIDITY

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company had incurred substantial losses from inception to date, the Company had a working capital deficit. These factors gave rise to substantial doubt that the Company would continue as a going concern. As of June 30, 2022, the Company had $68,057 of cash and no revenue to meets its ongoing operating expenses, and liabilities of $809,818 all of which are due within 12 months, and as of June 30, 2022, the Company still had a working capital deficit; accordingly, the substantial doubt of the Company’s ability to continue as a going concern that existed at December 31, 2021 was not alleviated and is still outstanding at June 30, 2022 and up through the date of this report.

 

 

 9 

 

 

The financial statements for the six months ended June 30, 2022 and 2021 have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company anticipates future losses in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and, or, obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with loans or contributions from related parties and, or, the sale of common stock. There is no assurance that this series of events will be satisfactorily completed.

 

Financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that may be necessary if the Company is unable to continue as a going concern. 

 

NOTE 3 - DEBT

 

Notes Payable

 

During 2020, the Company entered into a note payable agreement with a vendor related to $75,000 of accounts payable. The note bears interest at 10% per annum and is due on demand.

 

Notes Payable related party

 

In May of 2018, the Company issued a $70,025 Note payable to a related party for cash proceeds received. The related party also paid $2,000 of expense on behalf of the Company. The note was unsecured, with no stated interest rate and is due on demand. In February 2021, the CEO of the Company paid $25,200 on behalf of the Company to settle the balance of the line of credit in full. The note was unsecured, with no stated interest rate and is due on demand. In May 2022, the Company repaid the 25,200 to the related party. As of June 30, 2022 and December 31, 2021, the Company owed $6,117 and 31,317, respectively, on this note payable.

 

Convertible Debt

 

On January 14, 2020, the Company entered into an unsecured convertible promissory note, with a principal amount of $40,000. The Company received net cash proceeds of $37,000 after payment of fees of $3,000. The convertible note bears interest at 10% and matures on January 14, 2021, with interest accruing at a rate of 22% if the Company is in default. Beginning six months after the issuance of the note, the holder may convert the note at any time through the maturity date into shares of common stock, to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. The conversion price is determined based on 61% of the lowest trading price during the 20 trading days prior to the conversion date. During the year ended December 31, 2020, the Company was in default of the agreement and incurred an additional $20,000 of principal, which was recorded as interest expense. The Company also recognized $37,956 of derivative loss associated with the additional principal.

 

On January 27, 2022, the Company entered into a settlement agreement with the lender related to the convertible promissory note dated January 14, 2020. Pursuant to the agreement the company issued 2,000,000 shares of common stock for the conversion of $4,000 of principal balance of the note and has agreed to repay the remaining balance of $45,000 in nine equal payments of $5,000, beginning on February 1, 2022. The settlement agreement resulted in the forgiveness of $11,000 in principal on the note. The Company issued an additional 10,000,000 shares to this lender in March 2022 for the conversion of $15,000 of principal. As of June 30, 2022 the Company owed $10,000 on this note.

 

The Company evaluated the embedded conversion feature within the above convertible promissory note under ASC 815-15 and ASC 815 -40 and determined embedded conversion feature does meets the definition of a liability on the date the note became convertible. The Company accounted for the intrinsic value of Conversion Feature inherent to the convertible promissory note and a total debt discount of $39,131 was recorded along with a day one derivative loss of $21,558. Unamortized debt discount costs were $0 as June 30, 2022 related to this convertible note.

 

 

 10 

 

 

In March 2021, the Company entered into a Senior Secured convertible promissory note for an aggregate principal amount of $588,235. The note had an original issue discount of $88,235, bears interest at the greater of Prime plus 8% or 14%. The cash proceeds are to be distributed in tranches, with the first tranche of $65,000 being advanced in March 2021, with $15,000 of the amount paying legal fees related to the note payable and $11,471 of the original issue discount was assigned to this tranche. Each tranche has a maturity date of 9 months from the date of funding of that tranche. The principal and accrued interest are convertible into shares of the Company’s common stock at a fixed price of $0.002. In the event of default, the conversion price will be 60% of the lowest intraday rice during the previous 21 days from conversion. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. The holder of these notes is not permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion.

 

In connection with promissory note, the Company issued 30,000,000 shares of stock to the lender as a deferred finance cost and granted a warrant to purchase 25,000,000 shares of common stock at a fixed price of $0.006 for a period of 10 years. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. Each additional tranche that is borrowed, the Company will issue shares of common stock in the amount of 393 multiplied by the principal amount advanced, and additional warrants for 327 multiplied by the principal amount advanced. The lender will receive an additional 25,000,000 warrants upon fully funding the convertible note payable. The common stock was valued at $0.004 per share for a total fair value of 120,000 and a relative fair value of $22,304, which was recorded as a debt discount. The warrants were valued using the Black-Scholes model with volatility, measurement date Treasury yield curve rate of ten-year bond, closing stock price, convertible period, and conversion price as inputs. The fair value of the warrants was determined to be $99,014, with a relative fair value of $18,403, which was recorded to debt discount.

 

On November 3, 2021 the second trance in the amount of $50,000 was advanced under the March 21, 2021 financing, with $8,824 of the original issue discount being assigned to this tranche. No additional shares or warrants have been issued related to this tranche.

 

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $58,824 was recorded on the note.

 

As of June 30, 2022, the company owed $135,294 under the promissory note. Unamortized debt discount was $7,326 as of June 30, 2022, with $39,000 of amortization of debt discount during the six months ended June 30, 2022.

 

In November 2021, the Company entered into a Secured convertible promissory note for an aggregate principal amount of $58,889. The Company received net cash proceeds of $46,500 after an original issue discount of $8,889 and legal fees of $3,500. The convertible note bears interest at 12% and matures on May 16, 2022, with interest accruing at a rate of 24% if the Company is in default. The principal and accrued interest are convertible into shares of the Company’s common stock at a fixed price of $0.002 in the event of default. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price.

 

In connection with promissory note, the Company issued 20,000,000 shares of stock to the lender as a deferred finance cost and granted a warrant to purchase 9,814,815 shares of common stock at a fixed price of $0.006 for a period of 5 years. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. The common stock was valued at $0.0042 per share for a total fair value of 84,000 and a relative fair value of $23,019, which was recorded as a debt discount. The warrants were valued using the Black-Scholes model with volatility, measurement date Treasury yield curve rate of ten-year bond, closing stock price, convertible period, and conversion price as inputs. The fair value of the warrants was determined to be $39,187, with a relative fair value of $10,739, which was recorded to debt discount.

 

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $12,743 was recorded on the note.

 

 

 11 

 

 

As of June 30, 2022, the company owed $8,889 under the promissory note. Unamortized debt discount was $0 as of June 30, 2022, with $44,248 of amortization of debt discount during the six months ended June 30, 2022.

 

On March 29, 2022, the Company entered into a secured convertible promissory note, with a principal amount of $7,500. The convertible note bears interest at 14% and matures on March 29, 2023, with interest accruing at a rate of 22% if the Company is in default. The holder may convert the note at a rate of $0.001 at any time through the maturity date into shares of common stock, to the extent and provided that no holder of this note was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. In the event of a default by the Company under the terms of the note, the conversion price will be 60% of the lowest trading price of the Company’s common stock with the previous 21 days.

 

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $7,500 was recorded on the note.

 

As of June 30, 2022, the company owed $7,500 under the promissory note. Unamortized debt discount was $5,589 as of June 30, 2022, with $1,911 of amortization of debt discount during the six months ended June 30, 2022.

 

In April 2022, the Company entered into a Secured convertible promissory note for an aggregate principal amount of $27,778. The Company received net cash proceeds of $22,000 after an original issue discount of $2,778 and legal fees of $2,500. The convertible note bears interest at 12% and matures on October 6, 2022, with interest accruing at a rate of 24% if the Company is in default. The principal and accrued interest are convertible into shares of the Company’s common stock at a fixed price of $0.001 in the event of default. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price.

 

In connection with promissory note, the Company granted a warrant to purchase 6,250,000 shares of common stock at a fixed price of $0.004 for a period of 5 years. If the Company issues or sells common stock or any instrument that is convertible or exercisable into common stock at a price less than the fixed conversion price, the fixed conversion price shall be reset to such lower price. The warrants were valued using the Black-Scholes model with volatility, measurement date Treasury yield curve rate of ten-year bond, closing stock price, convertible period, and conversion price as inputs. The fair value of the warrants was determined to be $18,714, with a relative fair value of $10,112, which was recorded to debt discount.

 

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $11,888 was recorded on the note.

 

As of June 30, 2022, the company owed $27,778 under the promissory note. Unamortized debt discount was $14,876 as of June 30, 2022, with $12,902 of amortization of debt discount during the six months ended June 30, 2022.

 

On May 9, 2022, the Company entered into a secured convertible promissory note, with a principal amount of $75,000 in exchange for services rendered to the Company. The convertible note bears interest at 10% and matures on November 9, 2022, with interest accruing at a rate of 22% if the Company is in default. The holder may convert the note at a rate of $0.0015 at any time through the maturity date into shares of common stock, to the extent and provided that no holder of this note was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion.

 

The Company evaluated the embedded conversion feature within the above convertible note payable under ASC 815-15 and ASC 815-40 and determined embedded conversion feature does not meet the definition of a liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the relative fair value of the convertible notes payable and a total debt discount of $75,000 was recorded on the note.

 

As of June 30, 2022, the company owed $75,000 under the promissory note. Unamortized debt discount was $53,804 as of June 30, 2022, with $21,196 of amortization of debt discount during the six months ended June 30, 2022.

 

 

 12 

 

 

NOTE 4 - DERIVATIVE LIABILITIES

 

As discussed in Note 3 – Convertible Notes Payable, the Company analyzed the conversion features of the agreements for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion features should be classified as a derivative because the exercise price of these convertible notes are subject to a variable conversion rate. The Company has determined that the conversion feature is not considered to be solely indexed to the Company’s own stock and is therefore not afforded equity treatment. In accordance with AC 815, the Company has bifurcated the conversion feature of the notes and recorded a derivative liability.

 

The embedded derivatives for the notes are carried on the Company’s balance sheet at fair value. The derivative liability is marked- to-market each measurement period and any unrealized change in fair value is recorded as a component of the income statement and the associated fair value carrying amount on the balance sheet is adjusted by the change.

 

The fair value of the embedded derivatives for the notes were determined using the Black-Scholes option pricing model based on the following assumptions during the six months ending June 30, 2022: (1) dividend yield of 0%, (2) expected volatility ranging from 198% - 285%, (3) risk- free interest rate ranging from 0.43% – 2.51%, (4) expected life 0.5 – 0.75 year, and (5) estimated fair value of the Company’s common stock ranging from $0.0025 - $0.0049 per share. The instruments were fair valued at the date it was settled and the period end date of June 30, 2022.

 

The table below presents the change in the fair value of the derivative liability:

    
Fair value as of December 31, 2021   219,625 
Fair value on the date of issuance recorded as debt discounts    
Settlement of derivative upon repayment of notes   (35,932)
Settlement of derivative upon conversion of notes   (51,837)
Gain on change in fair value of derivatives   (112,553)
Fair value as of June 30, 2022  $19,303 

 

NOTE 5 - STOCKHOLDERS EQUITY

 

In March 2019, the Board of Directors of the Company amended the Company’s articles of incorporation to increase the authorized common shares to 975,000,000. On July 17, 2019, the Board of Directors approved the below Corporate Actions and recommended to the stockholders of the Company that they approve the Corporate Actions. On July 17, 2019, a majority of the Company’s stockholders, approved the following actions:

 

● The granting of discretionary authority to the Board, at any time or times for a period of 12 months after the date of the Written Consent, to adopt an amendment to the Certificate, to effect a reverse stock split at a ratio of a minimum of 1 to 5 and a maximum of 1 to 500, such ratio to be determined by the Board, or to determine not to proceed with the reverse stock split (the “Reverse Stock Split”); and

 

● The approval of an amendment to the Certificate increasing the number of shares of Common Stock the Company is authorized to issue from 975,000,000 to 4,000,000,000 as provided for herein (the “Increase in Authorized Shares”, and together with the Reverse Stock Split, the “Corporate Actions”).

 

The Reverse Stock Split has not been executed to date.

 

During the six months ended June 30, 2022 the company issued 60,000,000 shares of common stock for cash proceeds of $240,000

 

During the six months ended June 30, 2022 the company issued 12,000,000 shares of common stock for the conversion of $19,000 of principal on convertible notes as discussed in Note 3.

 

During the six months ended June 30, 2022 the company issued 15,200,000 shares of common stock as compensation for services with a fair value of $37,240.

 

 

 13 

 

 

Stock Warrants

 

The following table represents the warrant activity for the six months ended June 30, 2022. All warrants are accounted for as equity instruments:

            
   Stock Warrants 
   Shares   Weighted Average Exercise Price   Weighted Average Grant Date Fair Value 
Outstanding at December 31, 2021   34,814,815   $0.006   $0.006 
Granted   6,250,000   $0.004   $0.004 
Cancelled            
Expired            
Exercised            
Outstanding at June 30, 2022   41,064,815   $0.006   $0.006 
Exercisable at June 30, 2022   41,064,815   $0.006   $0.006 

 

Outstanding warrants at June 30, 2022 had an aggregate intrinsic value of $0.

 

Series A Preferred Stock

 

During the year ended December 31, 2018 the Company sold 1 share of Series A Preferred Stock in exchange for $232,500. Each share of Series A Preferred Stock has the voting rights of 350,000,000 shares. The Series A Preferred stock has no liquidation preference, and is not entitled to any dividends paid to common stockholders.

 

NOTE 6 - LEASES

 

The Company has operating leases for its administrative offices. For purposes of calculating operating lease liabilities, lease terms may be deemed to include options to extend the lease when it is reasonably certain that the Company will exercise those options. Some leasing arrangements require variable payments that are dependent on usage, output, or may vary for other reasons, such as insurance and tax payments. The variable lease payments are not presented as part of the initial ROU asset or lease liability. The Company’s lease agreements do not contain any material restrictive covenants.

 

At adoption of ASC 842, the Company recognized right of use assets and liabilities for operating leases of $102,878 related to its office space lease, which has a monthly payment of $4,134 and expires in March 2021. As part of the Infusionz Acquisition, the Company assumed the business’ operating lease for warehouse space. The Company recognized preliminary estimates of the right of use assets and liabilities related of this operating lease of $23,315. The lease has a monthly payment of $4,000 through August 31, 2019. The Infusionz business also has two rental agreements with total payments of $3,800 per month with month to month terms. In April 2018, Pura Vida Vitamins LLC entered into a month to month rental agreement for office space for $1,000 per month. 

 

During the year ended December 31, 2019, the Company entered into a real estate lease for office and warehouse space in Colorado. The lease has monthly payments ranging from approximately $19,500 to $23,700 over the lease term of 54 months. The Company has an option to acquire the leased premises at the conclusion of the lease for a purchase price of $3,500,000. Under ASC 842, this lease was determined to be an operating lease, and a right of use asset and lease liability of $928,372 was recognized at commencement of the lease. The Company did not consider the purchase option to be reasonably certain of exercise in its analysis of the lease. The Company paid a security deposit of $58,749 at commencement, along with first and last month’s rent, for a total of $102,000. During the year ended December 31, 2020, the Company was notified by its landlord to vacate the premises and lost the use of the asset. The landlord subleased the property and agreed to accept one year of payments as final settlement of the lease. The Company recognized a loss on settlement of $172,740 related to this lease.

 

 

 14 

 

 

During the year ended December 31, 2020, the Company agreed to settle an existing lease in exchange for a note payable of $15,214, which bears interest at 10% or 22% in the event of default. As of the date of this report, the Company is in default of this note. The Company recognized a loss on settlement of $6,944 related to this agreement.

 

The following table summarizes the lease-related assets and liabilities recorded in the consolidated balance sheet at June 30, 2022 and December 31, 2021:

        
Lease Position  June 30, 2022   December 31, 2021 
         
Operating lease right-of-use assets  $   $ 
Right of use liability operating lease short term   242,001    242,001 
Right of use liability operating lease long term        
Total operating lease liabilities  $242,001   $242,001 

 

The Company recognized operating lease cost of $0 and $0 for the six months ended June 30, 2022 and 2021, respectively. The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable.

 

The following table provides the maturities of lease liabilities at June 30, 2022:

    
Maturity of Lease Liabilities at June 30, 2022  Operating Leases 
2022  $242,001 
2023    
2024    
2025    
2026    
2027 and thereafter    
Total future undiscounted lease payments  $242,001 
Less: Interest    
Present value of lease liabilities  $242,001 

 

At June 30, 2022, the Company had no additional leases which had not yet commenced.

  

 

NOTE 7 - SUBSEQUENT EVENTS

 

The Company evaluates subsequent events that have occurred after the balance sheet date of June 30, 2022 and up through August 15, 2022, which is the date that these financial statements are available to be issued. There are two types of subsequent events: (i) recognized, or those that provide additional evidence with respect to conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements, and (ii) non-recognized, or those that provide evidence with respect to conditions that did not exist at the date of the balance sheet but arose subsequent to that date.

 

On July 29, 2022, a lender converted $46,688 of accrued interest and fees into 25,000,000 shares of common stock.

 

 

 

 15 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q. The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere in this report.

 

Company Overview

 

The Company

 

Golden Developing Solutions, Inc. (the “Company,” “we,” “our,” or “us”) was originally incorporated on December 17, 1998 in the State of Nevada under the name American Associates Group. In 2007 the name was changed to Clean Hydrogen Producers, Ltd before being changed in April of 2017 to Golden Developing Solutions, Inc. The Company has structured itself in 2017 as a cannabis holding company and intends to make additional acquisitions in the industry in the near future.

 

On September 26, 2018, the Company incorporated Tasos Media LLC as a wholly owned subsidiary.

 

On March 9, 2019, the Company incorporated CBD Infusionz, LLC as a wholly owned subsidiary.

 

On October 4, 2019 the Company entered into a Termination Agreement (the “Termination Agreement”) with Infusionz, LLC, a Colorado limited liability company (“Infusionz”) on October 4, 2019 (the “Closing Date”), whereby the Company and Infusionz elected to terminate the March 8, 2019 Asset Purchase Agreement (the “Asset Purchase Agreement”). The Asset Purchase Agreement resulted in the Company’s acquisition of Infusionz’s assets. Infusionz and the Company agreed to unwind the Company’s acquisition of Infusionz’s assets pursuant to the terms of the Asset Purchase Agreement.

 

The Termination Agreement provides that Infusionz and all associated members will return the stock consideration granted to them pursuant to the Asset Purchase Agreement. The fair value of the stock consideration to be returned to the Company is approximately $2,600,000. The Termination Agreement provides that Infusionz will release the Company from the promissory note issued as payment for the assets pursuant to the Asset Purchase Agreement (the “Original Note”) and any and all obligations therein. The Termination Agreement provides that the Company will issue two unsecured promissory notes to Infusionz each in the principal amount of $25,000 with neither of these notes being convertible (the “Notes”). The Termination Agreement further provides that the Company will assign, and Infusionz will assume, certain assets and contracts as defined therein.

 

The Notes became effective as of the Closing Date, and both Notes were due and payable on December 31, 2020 and remain outstanding as of August 15, 2022 in the amount of $50,000.

 

On December 1, 2021, the Company incorporated Renown Pharmaceuticals LLC as a wholly owned subsidiary in the state Florida. In July 2022, the domicile was move to Delaware.

 

Operations

 

Golden Developing Solutions, Inc. (the “Company”) is developing an online retail business for CBD, hemp oil and health/wellness related products. Through our online retail business, we will offer a broad range of price-competitive products, including traditional vitamins, supplements, and CBD based tinctures, vapes, softgels, among other products.

 

 

 16 

 

 

We will sell our products and services through our Internet website (the "Website"). The Company is developing an online store whose merchandise includes hemp related products, CBD (Cannabidiol) related products and additional products focusing on health and lifestyle.

 

Initially, we intend to carry in excess of 10 products from two suppliers. We intend to place directed advertising throughout the online store. Advertising will originate through internet or direct-advertising sales by the Company. The company may also use social media outlets such as Facebook, Twitter and Instagram in an effort to attract customers with product specific advertisements or posts.

 

As an online retail store operating with distribution hub, we will be able to rapidly scale our products and services with minimal marginal costs. Each additional brand, category or product that we add to our platform adds negligible server hosting costs. It also allows us to have a virtual presence and exposure to every regulated cannabis market without establishing a costly physical presence in each state. This minimizes the costs of scaling and required capital while, at the same time, offering a direct role in the cannabis industry without ever touching the plant itself.

 

We are a startup company in the cannabis industry. Our focus is to create online sales and marketing initiatives to build a dominate brand. Our oil and extracts division will focus on online sales of formulated CBD / hemp oil tinctures, softgels, capsules. We have our Website under development and anticipate to be online in the next few months. We are in the process of acquiring trademarks relative to our products. Agreements with raw material suppliers and related products have been obtained. All supply will come domestically with white label agreements when needed. Online Marketing program in place to drive fast paced growth plan in line with industry. Orders will be handled online and shipped via appropriate carriers from our inventory in leased warehouse. Drop shipping may be used during initial launch phases. Customers for CBD/hemp products expect the highest of quality and consistency and pricing is based on those levels. We expect to be price and quality competitive on the higher end of that scale. All product quality is 100% customer satisfaction guaranteed and products not deemed to be of quality can be returned for a refund. Quality and consistency of quality are needed to avoid returned product issues which could result in financial liability. Online payment gateway being established with backup vendor for online payment gateway in place as well.

 

Results of Operations

 

Three months ended June 30, 2022 compared to three months ended June 30, 2021

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses amounted to $50,656 and $324, respectively for the three months ended June 30, 2022 and 2021, an increase of $50,332 due to increased consulting fees in the current period.

 

Professional fees

 

Professional fees amounted to $112,489 and $12,159 respectively for the three months ended June 30, 2022 and 2021. The increase of $100,330 was due to increased investor relations along with audit and accounting related expenses to bring the Company’s reporting requirements current.

 

Interest expense

 

Interest expense was $83,418 and $41,415 for the three months ended June 30, 2022, and 2021, respectively.

        

Other Income/Expense

 

The Company recognized gain of $23,574 for the three months ended June 30, 2022 compared to a gain of $31,011 from the change in fair value of derivative liabilities during the three months ended June 30, 2021. 

 

 

 17 

 

 

Six months ended June 30, 2022 compared to six months ended June 30, 2021

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses amounted to $96,865 and $5,713, respectively for the six months ended June 30, 2021 and 2020, an increase of $91,152 due to increased consulting fees in the current period as the Company increased its operations to raise additional funds.

 

Professional fees

 

Professional fees amounted to $124,510 and $20,459 respectively for the six months ended June 30, 2021 and 2020. The increase of $104,051 was due to increased investor relations along with audit and accounting related expenses bring the Company’s reporting requirements current.

 

Interest expense

 

Interest expense was $145,027 and $63,910 for the six months ended June 30, 2021, and 2020, respectively.

 

Other Income/Expense

 

The Company recognized a gain of $11,000 from extinguishment of liabilities and a derivative gain of $148,465 during the six months ended June 30, 2022, compared to a gain of $58,617 from extinguishment of liabilities and a derivative loss of $82,259 during the six months ended June 30, 2021.

 

Liquidity and Capital Resources

 

The following is a summary of the Company’s cash flows used in operating activities for the six months ended June 30, 2022 and 2021:

 

  

Six Months ended

June 30, 2022

  

Six Months ended

June 30, 2021

 
Net cash used in operating activities   (116,978)   (48,589)
Net cash used in investing activities        
Net cash provided by financing activities   174,300    50,000 

 

Operating Activities

 

The cash used in operating activities from continuing operations of $116,978 for the six months ended June 30, 2022 was primarily due working capital and general and administrative expenses during the period.

 

Financing Activities

 

The cash provided by financing activities from continuing operations of $174,300 during the six months ended June 30, 2022 was from the proceeds of $240,000 from issuance of common shares, and $29,500 proceeds from issuance of a convertible note, offset by payments on convertible notes of $70,000.

 

We are a public company and as such we have incurred and will continue to incur significant expenses for legal, accounting and related services. As a public entity, subject to the reporting requirements of the Exchange Act of 1934, we incur ongoing expenses associated with professional fees for accounting, legal and a host of other expenses including annual reports and proxy statements, if required. We estimate that these costs will increase over the next few years and may be significantly higher if our business volume and transactional activity increases. These obligations will certainly reduce our ability and resources to expand our business plan and activities.

 

 

 18 

 

 

Going Concern

 

As of June 30, 2022, the Company had $68,057 of cash and had no revenue during the six months ended June 30, 2022 to meets its ongoing operating expenses and liabilities of $809,818 all of which are due within 12 months.

 

Our auditor has issued a “going concern” qualification as part of its opinion in the Audit Report for the year ending December 31, 2021, and our unaudited financial statements for the quarter ended six months ended June 30, 2022, include a “going concern” note disclosing that our ability to continue as a going concern is contingent on us being able to raise working capital to grow our operations and generate revenue.

 

Critical Accounting Policies

 

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable under the circumstances; however, actual results may vary from these estimates and assumptions.

 

Recently Issued Accounting Pronouncements

  

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements. 

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures: Our management carried out an evaluation of the effectiveness and design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the Exchange Act). Based on that evaluation, our Chief Executive Officer and Principal Financial Officer has concluded that, at September 30, 2019, such disclosure controls and procedures were not effective due to the existing of the following material weaknesses:

 

  Lack of segregation of duties. The Company did not effectively segregate certain accounting duties due to the small size of its accounting staff.

 

 

 19 

 

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management including our Chief Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

 

Limitations on the Effectiveness of Controls: Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Our Chief Executive Officer and Principal Financial Officer has concluded, based on his evaluation as of the end of the period covered by this Quarterly Report that our disclosure controls and procedures were not sufficiently effective to provide reasonable assurance that the objectives of our disclosure control system were met.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

 

 20 

 

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is not involved in any disputes and does not have any litigation matters pending. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company, threatened against or affecting our Company or our common stock, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors.

 

Not Applicable

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

The Company is in default of the following debt instruments:

 

  $15,214 note payable from lease settlement bearing interest at 18%
     
  $50,000 note payable accruing interest at a default rate of 15% per year and a default rate of 15%, arising from the sale of the Infusionz Business.
     
  $75,000 note payable accruing interest at 10%
     
  $10,000 convertible note payable accruing interest at a default rate of 22% per year.

 

Item 4. Mine Safety Disclosure.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

 

 

 21 

 

 

Item 6. Exhibits.

 

        Incorporated by    
Exhibit       Reference   Filed or Furnished
Number   Exhibit Description   Form   Exhibit   Filing Date   Herewith
3.1   Articles of Incorporation, as amended   10-12(g)   3.1   05/01/2019    
3.2   Series A Certificate of Designation   10-12(g)   3.2   05/01/2019    
3.3   By-laws   10-12(g)   3.3   05/01/2019    
3.4   Certificate of Amendment to Amended and Restated Articles of Incorporation, dated September 13, 2018   10-12(g)/A   3.4   07/02/2019    
3.5   Certificate of Amendment to Amended and Restated Articles of Incorporation, dated March 6, 2019   10-12(g)/A   3.5   07/02/2019    
4.1   Form of 3% Promissory Note issued September 18, 2018, to Tyler Bartholomew, David Lindauer, Bill Anders and Brad Billman   10-12(g)   4.1   05/01/2019    
4.2   Form of 3% Promissory Note issued March 8, 2019, to the Owners of Infusionz LLC   10-12(g)   4.2   05/01/2019    
10.1   Binding Joint Venture Term Sheet, dated August 15, 2018, between Pura Vida Health LLC and Golden Developing Solutions, Inc.   10-12(g)/A   10.1   07/02/2019    
10.2   Asset Purchase Agreement dated September 18, 2018, by and among Golden Developing Solutions, Inc. and Layer Six Media, Inc.   10-12(g)   10.2   05/01/2019    
10.3   Asset Purchase Agreement dated March 8, 2019, by and between Golden Developing Solutions, Inc., Tyler Bartholomew, David Lindauer, Bill Anders and Brad Billman   10-12(g)   10.3   05/01/2019    
10.4   Asset Purchase Agreement dated March 8, 2019, by and between Golden Developing Solutions, Inc. and Infusionz, LLC   10-12(g)   10.4   05/01/2019    
10.5   Form of Employment Agreement entered into with David Lindauer   10-12(g)   10.5   05/01/2019    
10.6   Form of Employment Agreement entered into with Tyler Bartholomew   10-12(g)   10.5   05/01/2019    
10.7   Settlement Agreement by and between Golden Developing Solutions, Inc. and Pura Vida Vitamins, LLC   10-12/(g)/A   10.7   08/14/2019    
21.1   List of Subsidiaries   10-12(g)   21.1   05/01/2019    
31.1   Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14 and 15d-14.               X
31.2   Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a-14 and 15d-14.               X
32.1   Certification of the Company’s Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.               X
101.INS*   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)                
101.SCH*   Inline XBRL Taxonomy Extension Schema Document                
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document                
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document                
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document                
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document                
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document)                

 

  * Filed herewith.

 

  ** In accordance with SEC Release 33-8238, Exhibit 32.1 is furnished and not filed.

 

 22 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GOLDEN DEVELOPING SOLUTIONS, INC.
     
Date: August 15, 2022 By: /s/ Stavros Triant
    Chief Executive Officer

 

 

 

 23 

 

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Stavros Triant, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Golden Developing Solutions, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022

 

/s/ Stavros Triant  
Stavros Triant  
Chief Executive Officer  
(Principal Executive Officer)  

Exhibit 31.2

 

 

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Stavros Triant, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Golden Developing Solutions, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022

 

/s/ Stavros Triant  
Stavros Triant, Chief Executive Officer  
(Principal Financial Officer and Principal Accounting Officer)  

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Stavros Triant, Chief Executive Officer, of Golden Developing Solutions, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) the quarterly report on Form 10-Q of Golden Developing Solutions, Inc. for the period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Golden Developing Solutions, Inc.

 

Dated: August 15, 2022 

 

/s/ Stavros Triant  
Stavros Triant  
Chief Executive Officer  
(Principal Executive Officer)  

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Golden Developing Solutions, Inc. and will be retained by Golden Developing Solutions, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Stavros Triant, Principal Financial Officer and Principal Accounting Officer, of Golden Developing Solutions, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) the quarterly report on Form 10-Q of Golden Developing Solutions, Inc. for the period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Golden Developing Solutions, Inc.

 

Dated: August 15, 2022

 

/s/ Stavros Triant  
Stavros Triant, Chief Executive Officer  
(Principal Financial Officer and Principal Accounting Officer)  

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Golden Developing Solutions, Inc. and will be retained by Golden Developing Solutions, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings